Skip links

Hemgenix® (etranacogene dezaparvovec-drlb)

Full Name Hemgenix® (etranacogene dezaparvovec-drlb)
Drug Hemgenix
Manufacturer CSL Behring
Route of Administration Intravenous
Site of Care Healthcare Facility
Approved Indication The treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes
Disease Hemophilia B
Therapeutic Area Hematology; Cell & Gene Therapy
Enrollment Form Link Enrollment Form
Phone Number 800-975-8693
Fax Number 877-740-7535
Product Website